Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
This article was originally published in The Tan Sheet
Executive Summary
Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said
You may also be interested in...
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers